Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

mRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in ... Moreover, most people only show minor symptoms after contracting it. The Recent Price Action of MRNA Stock In the last month ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says. Though most people recover from the ...